Pharmaceutical Executive-12-01-2011

RaQualia's New Spin on the Startup

It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?

Agency expansion and globalization promote innovation, collaboration, and organizational changes

Even as the global economic roller coaster affects one of the country's dearest public institutions-the National Health Service-there is still reason for optimism in these times of austerity

Thorough risk assessment is essential before placing bets on good evidence that clears a path to approval.

Patients want to take a more active role in treatment decisions. Drug facts boxes in DTC ads represent a crucial element of informed consent.

Pharm Exec sits down with CEO Atsushi Nagahisa to explore how culture can maximize the value of an inherited portfolio

The effect on pharma of the EU's Transparency Directive has been overly constraining, but will the mooted revisions offer any room to maneuver?

The pharmaceutical industry in Britain is a key sesctor in the full economic recovery of the country

Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma - but is it? Pharm Exec convenes an expert round table to examine how best to make progress and agree on some practical steps for incorporation in the campaign agenda.

The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item, writes William Looney.